{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:44:30Z","timestamp":1789764270554,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Science Center, Poland","award":["2015\/18\/E\/NZ2\/00678"],"award-info":[{"award-number":["2015\/18\/E\/NZ2\/00678"]}]},{"name":"National Science Center, Poland","award":["2018\/29\/B\/NZ1\/00293"],"award-info":[{"award-number":["2018\/29\/B\/NZ1\/00293"]}]},{"name":"the National Science Center","award":["2015\/18\/E\/NZ2\/00678"],"award-info":[{"award-number":["2015\/18\/E\/NZ2\/00678"]}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.omtn.2019.12.012","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:54:54Z","timestamp":1576709694000},"page":"562-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression"],"prefix":"10.1016","volume":"19","author":[{"given":"Anna","family":"Kotowska-Zimmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Ostrovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Olejniczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2019.12.012_bib1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0896-6273(02)00872-3","article-title":"Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington\u2019s disease and related disorders","volume":"35","author":"Ross","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.12.012_bib2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3727\/096368914X678454","article-title":"Polyglutamine (PolyQ) diseases: genetics to treatments","volume":"23","author":"Fan","year":"2014","journal-title":"Cell Transplant."},{"key":"10.1016\/j.omtn.2019.12.012_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/neup.12433","article-title":"Deregulation of autophagy in postmortem brains of Machado-Joseph disease patients","volume":"38","author":"Sittler","year":"2018","journal-title":"Neuropathology"},{"key":"10.1016\/j.omtn.2019.12.012_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-012-1000-x","article-title":"Brain pathology of spinocerebellar ataxias","volume":"124","author":"Seidel","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.omtn.2019.12.012_bib5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin Lowering Strategies for Disease Modification in Huntington\u2019s Disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.12.012_bib6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s13311-018-00696-y","article-title":"Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias","volume":"16","author":"Buijsen","year":"2019","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.omtn.2019.12.012_bib7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtn.2019.12.012_bib8","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41582-018-0051-6","article-title":"Spinocerebellar ataxias: prospects and challenges for therapy development","volume":"14","author":"Ashizawa","year":"2018","journal-title":"Nat. Rev. Neurol."},{"issue":"R1","key":"10.1016\/j.omtn.2019.12.012_bib9","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1093\/hmg\/ddv442","article-title":"Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington\u2019s disease and spinocerebellar ataxia","volume":"25","author":"Keiser","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.12.012_bib10","doi-asserted-by":"crossref","first-page":"873860","DOI":"10.1155\/2015\/873860","article-title":"The role of the immune system in triplet repeat expansion diseases","volume":"2015","author":"Olejniczak","year":"2015","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.omtn.2019.12.012_bib11","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: From current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. A."},{"key":"10.1016\/j.omtn.2019.12.012_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.4003","article-title":"PPAR-\u03b4 is repressed in Huntington\u2019s disease, is required for normal neuronal function and can be targeted therapeutically","volume":"22","author":"Dickey","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2019.12.012_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/med.21425","article-title":"Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts","volume":"37","author":"Esteves","year":"2017","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.omtn.2019.12.012_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 Editing of the Mutant Huntingtin Allele In\u00a0Vitro and In\u00a0Vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.12.012_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2018.00075","article-title":"Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases","volume":"12","author":"Dabrowska","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.omtn.2019.12.012_bib16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.omtn.2019.12.012_bib17","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","article-title":"The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes","volume":"20","author":"Merienne","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2019.12.012_bib18","first-page":"4566","article-title":"Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9","volume":"25","author":"Shin","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.12.012_bib19","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting huntingtin expression in patients with Huntington\u2019s disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2019.12.012_bib20","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2019.12.012_bib21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2019.12.012_bib22","first-page":"88","article-title":"Multicenter, Randomized, Double-blind, Placebo-controlled Phase 1b\/2a Studies of WVE-120101 and WVE-120102 in Patients with Huntington\u2019s Disease (P2.006)","volume":"2017","author":"Hersch","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2019.12.012_bib23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In\u00a0vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.12.012_bib24","doi-asserted-by":"crossref","first-page":"7195","DOI":"10.1073\/pnas.1231012100","article-title":"Allele-specific silencing of dominant disease genes","volume":"100","author":"Miller","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.12.012_bib25","doi-asserted-by":"crossref","first-page":"9570","DOI":"10.1093\/nar\/gkt693","article-title":"ss-siRNAs allele selectively inhibit ataxin-3 expression: multiple mechanisms for an alternative gene silencing strategy","volume":"41","author":"Liu","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.12.012_bib26","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1021\/bi500610r","article-title":"Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs","volume":"53","author":"Hu","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.omtn.2019.12.012_bib27","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.chembiol.2010.10.013","article-title":"Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism","volume":"17","author":"Hu","year":"2010","journal-title":"Chem. Biol."},{"key":"10.1016\/j.omtn.2019.12.012_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/nat.2013.0476","article-title":"Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs","volume":"24","author":"Hu","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2019.12.012_bib29","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2019.12.012_bib30","doi-asserted-by":"crossref","first-page":"10426","DOI":"10.1093\/nar\/gkt825","article-title":"Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression","volume":"41","author":"Fiszer","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.12.012_bib31","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1093\/nar\/gks907","article-title":"Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway","volume":"40","author":"Hu","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.12.012_bib32","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.3390\/genes7120132","article-title":"Mutant CAG repeats effectively targeted by RNA interference in SCA7 cells","volume":"7","author":"Fiszer","year":"2016","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.omtn.2019.12.012_bib33","first-page":"759","article-title":"Silencing of genes responsible for polyQ diseases using chemically modified single-stranded siRNAs","volume":"63","author":"Fiszer","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.omtn.2019.12.012_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2199-13-6","article-title":"An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases","volume":"13","author":"Fiszer","year":"2012","journal-title":"BMC Mol. Biol."},{"key":"10.1016\/j.omtn.2019.12.012_bib35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbagrm.2016.02.014","article-title":"siRNA release from pri-miRNA scaffolds is controlled by the sequence and structure of RNA","volume":"1859","author":"Galka-Marciniak","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2019.12.012_bib36","doi-asserted-by":"crossref","first-page":"e234","DOI":"10.1038\/mtna.2015.7","article-title":"Artificial miRNAs targeting mutant huntingtin show preferential silencing in\u00a0vitro and in\u00a0vivo","volume":"4","author":"Monteys","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2019.12.012_bib37","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington\u2019s Disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2019.12.012_bib38","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1093\/nar\/gkq127","article-title":"Trinucleotide repeats in human genome and exome","volume":"38","author":"Kozlowski","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2019.12.012_bib39","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/hmg\/10.10.1093","article-title":"Paternal monoallelic expression of PEG3 in the human placenta","volume":"10","author":"Hiby","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2019.12.012_bib40","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1074\/jbc.M109.069450","article-title":"The imprinted gene PEG3 inhibits Wnt signaling and regulates glioma growth","volume":"285","author":"Jiang","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtn.2019.12.012_bib41","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrn.2017.92","article-title":"Polyglutamine spinocerebellar ataxias - from genes to potential treatments","volume":"18","author":"Paulson","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtn.2019.12.012_bib42","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The Biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.omtn.2019.12.012_bib43","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1083\/jcb.150.5.939","article-title":"Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO\/MTG8 in the nuclear matrix and represses transcription","volume":"150","author":"Wood","year":"2000","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.omtn.2019.12.012_bib44","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awr333","article-title":"Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum","volume":"135","author":"Grondin","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.omtn.2019.12.012_bib45","first-page":"3","article-title":"The effects of huntingtin-lowering: what do we know so far?","volume":"9","author":"Kaemmerer","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.omtn.2019.12.012_bib46","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fgene.2012.00102","article-title":"SiRNA design software for a target gene-specific RNA interference","volume":"3","author":"Naito","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtn.2019.12.012_bib47","doi-asserted-by":"crossref","first-page":"e1004656","DOI":"10.1371\/journal.pcbi.1004656","article-title":"The siRNA Non-seed Region and Its Target Sequences Are Auxiliary Determinants of Off-Target Effects","volume":"11","author":"Kamola","year":"2015","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.omtn.2019.12.012_bib48","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.12.012_bib49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2019.12.012_bib50","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2019.12.012_bib51","doi-asserted-by":"crossref","first-page":"e99341","DOI":"10.1371\/journal.pone.0099341","article-title":"Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells","volume":"9","author":"Drouet","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2019.12.012_bib52","doi-asserted-by":"crossref","first-page":"e52396","DOI":"10.1371\/journal.pone.0052396","article-title":"Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice","volume":"8","author":"N\u00f3brega","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2019.12.012_bib53","doi-asserted-by":"crossref","first-page":"e3341","DOI":"10.1371\/journal.pone.0003341","article-title":"Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease","volume":"3","author":"Alves","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2019.12.012_bib54","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1038\/ejhg.2014.39","article-title":"Allele-specific silencing of mutant Ataxin-7 in SCA7 patient-derived fibroblasts","volume":"22","author":"Scholefield","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2019.12.012_bib55","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2019.12.012_bib56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2019.12.012_bib57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/gt.2011.10","article-title":"Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design","volume":"18","author":"Martin","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtn.2019.12.012_bib58","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1261\/rna.1062908","article-title":"Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs","volume":"14","author":"Boudreau","year":"2008","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2019.12.012_bib59","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2105-15-182","article-title":"Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads","volume":"15","author":"Jiang","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.omtn.2019.12.012_bib60","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2199-12-14","article-title":"Northern blotting analysis of microRNAs, their precursors and RNA interference triggers","volume":"12","author":"Koscianska","year":"2011","journal-title":"BMC Mol. Biol."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225311930407X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S216225311930407X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T02:01:53Z","timestamp":1715997713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S216225311930407X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":60,"alternative-id":["S216225311930407X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2019.12.012","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Universal RNAi Triggers for the Specific Inhibition of Mutant Huntingtin, Atrophin-1, Ataxin-3, and Ataxin-7 Expression","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2019.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}